Cargando…

SF3B1 Mutations in Hematological Malignancies

SIMPLE SUMMARY: In recent years, spliceosome mutations have become of diagnostic and prognostic interest in several malignancies, as alternative splice mRNA isoforms are often associated with neoplasia. The role played by SF3B1, one of the splicing factors most frequently mutated in cancer, in diffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cilloni, Daniela, Itri, Federico, Bonuomo, Valentina, Petiti, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563056/ https://www.ncbi.nlm.nih.gov/pubmed/36230848 http://dx.doi.org/10.3390/cancers14194927

Ejemplares similares

Detection of SF3B1 p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms
por: Petiti, Jessica, et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
por: Cilloni, Daniela, et al.
Publicado: (2019)

P998: REGULATION OF BCL-X SPLICING BY SRC KINASES INHIBITORS IN MYELOPROLIFERATIVE NEOPLASMS
por: Petiti, J., et al.
Publicado: (2022)

Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2020)

Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
por: Jovanovski, Aleksandar, et al.
Publicado: (2020)

The biological function and clinical significance of SF3B1 mutations in cancer
por: Zhou, Zhixia, et al.
Publicado: (2020)

Mutant SF3B1 promotes malignancy in PDAC
por: Simmler, Patrik, et al.
Publicado: (2023)

The metabolic reprogramming and vulnerability of SF3B1 mutations
por: Dalton, W. Brian
Publicado: (2020)

Somatic SF3B1 hotspot mutation in prolactinomas
por: Li, Chuzhong, et al.
Publicado: (2020)

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
por: Camus, Vincent, et al.
Publicado: (2017)

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS
por: Senapati, J., et al.
Publicado: (2022)

Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways
por: Petiti, Jessica, et al.
Publicado: (2019)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

NF-κB in Hematological Malignancies
por: Imbert, Véronique, et al.
Publicado: (2017)

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells
por: Rosso, Valentina, et al.
Publicado: (2019)

The SF3b complex: splicing and beyond
por: Sun, Chengfu
Publicado: (2020)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells
por: Vivet-Noguer, Raquel, et al.
Publicado: (2022)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome
por: Rujirachaivej, Punchita, et al.
Publicado: (2018)

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms
por: Rosso, Valentina, et al.
Publicado: (2016)

The role of BCL11B in hematological malignancy
por: Huang, Xin, et al.
Publicado: (2012)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

U2 snRNA structure is influenced by SF3A and SF3B proteins but not by SF3B inhibitors
por: Urabe, Veronica K., et al.
Publicado: (2021)

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma
por: Drabarek, Wojtek, et al.
Publicado: (2022)

Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
por: Schwaederlé, M, et al.
Publicado: (2013)

Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients
por: Pacholewska, Alicja, et al.
Publicado: (2021)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

Targeting CD22 for B-cell hematologic malignancies
por: Xu, Jia, et al.
Publicado: (2023)

The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy
por: Gallo, Daniela, et al.
Publicado: (2016)

Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3
por: Putowski, Maciej, et al.
Publicado: (2021)

Srs2 and Pif1 as Model Systems for Understanding Sf1a and Sf1b Helicase Structure and Function
por: Meir, Aviv, et al.
Publicado: (2021)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies
por: Saitta, Claudia, et al.
Publicado: (2022)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
por: Harbour, J. William, et al.
Publicado: (2013)

SF3B1 mutations constitute a novel therapeutic target in breast cancer
por: Maguire, Sarah L, et al.
Publicado: (2015)

Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract
por: Cai, Yuan-jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4g4dae8l9kmk9nvgm1qo6c9m6p